IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - C
IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.